Related Experiment Video
Updated: Jun 10, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Hepatitis B and C treatment: New perspectives
1Division of Medicine, Faculty of Medicine, Imperial College London, South Kensington Campus, London SW7 2AZ, United Kingdom.
Discovery Medicine
|August 14, 2010
Summary
Hepatitis B and C cause significant global health burdens, leading to cirrhosis and liver cancer. Recent advances offer new treatments for infected patients, including those with difficult-to-treat conditions.
Area of Science:
- Hepatology and Virology
Background:
- Hepatitis B and C viruses (HBV and HCV) are major global health concerns, causing liver inflammation, cirrhosis, and hepatocellular carcinoma (HCC).
- Millions worldwide are infected, with limited therapeutic options historically available.
- Recent advancements have improved patient assessment and treatment, with ongoing research focusing on resistant or co-infected populations.
Purpose of the Study:
- To review recent advances in the assessment and treatment of Hepatitis B and C.
- To highlight the clinical significance of viral markers and evolving therapeutic strategies.
Main Methods:
- Review of current literature on HBV and HCV epidemiology, pathogenesis, and treatment.
- Analysis of diagnostic markers such as hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg).
- Discussion of emerging therapeutic options and challenges in managing complex patient groups.
Main Results:
- HBV is a DNA virus transmitted sexually, vertically, and via blood, characterized by HBsAg and HBeAg.
- HBsAg persistence >6 months indicates chronic HBV infection; HBeAg presence signifies active viral replication and increased HCC risk.
- Precore mutants of HBV can exhibit high viral DNA without HBeAg, posing a risk for liver disease progression.
Conclusions:
- Significant progress has been made in managing HBV and HCV infections.
- Understanding viral markers like HBsAg, HBeAg, and precore mutants is crucial for risk assessment and treatment.
- New therapeutic strategies are expanding options for patients, including those with challenging clinical scenarios.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...